Mechelen, Belgium; 6 January 2022, 15.30 CET – Galapagos NV (Euronext & NASDAQ: GLPG) will participate in the 40 th A nnual J.P. Morgan Healthcare Conference on January 10-13 , 20 22.
Onno van de Stolpe, CEO, will present on Thursday, January 13 at 14.15 CET (8.15 a.m. ET). The presentation will be a live audio webcast and can be accessed via the following link . A replay of the webcast will be available on the Galapagos’ website at www.glpg.com .
About Galapagos
Galapagos NV discovers, develops, and commercializes small molecule medicines with novel modes of action. Our pipeline comprises discovery through Phase 3 programs in inflammation, fibrosis, and other indications. Our ambition is to become a leading global biopharmaceutical company focused on the discovery, development, and commercialization of innovative medicines. More information at www.glpg.com .
C ontacts
Invest ors :
Sofie Van Gijsel
Head of Investor Relations
+1 781 296 1143
Sandra Cauwenberghs
Director Investor Relations
+32 495 58 46 63
ir@glpg.com
Media:
Marieke Vermeersch
Head of Corporate Communications
+32 479 49 06 03
communications@glpg.com
Forward-looking statements
This release may contain forward-looking statements. Such forward-looking statements are not guarantees of future results. These forward-looking statements speak only as of the date of publication of this document. Galapagos expressly disclaims any obligation to update any forward-looking statements in this document, unless specifically required by law or regulation.
Attachment